MA53010A - Formulations d'un inhibiteur de axl/mer - Google Patents

Formulations d'un inhibiteur de axl/mer

Info

Publication number
MA53010A
MA53010A MA053010A MA53010A MA53010A MA 53010 A MA53010 A MA 53010A MA 053010 A MA053010 A MA 053010A MA 53010 A MA53010 A MA 53010A MA 53010 A MA53010 A MA 53010A
Authority
MA
Morocco
Prior art keywords
axl
formulations
mer inhibitor
mer
inhibitor
Prior art date
Application number
MA053010A
Other languages
English (en)
Inventor
Francis X Muller
William L Rocco
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA53010A publication Critical patent/MA53010A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053010A 2018-06-29 2019-06-28 Formulations d'un inhibiteur de axl/mer MA53010A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862692210P 2018-06-29 2018-06-29

Publications (1)

Publication Number Publication Date
MA53010A true MA53010A (fr) 2021-05-05

Family

ID=67297438

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053010A MA53010A (fr) 2018-06-29 2019-06-28 Formulations d'un inhibiteur de axl/mer

Country Status (21)

Country Link
US (2) US11241438B2 (fr)
EP (1) EP3813800A1 (fr)
JP (1) JP7520732B2 (fr)
KR (1) KR20210049088A (fr)
CN (2) CN113164398B (fr)
AR (1) AR117600A1 (fr)
AU (1) AU2019293618A1 (fr)
BR (1) BR112020026804A2 (fr)
CA (1) CA3105214A1 (fr)
CL (1) CL2020003397A1 (fr)
CO (1) CO2021000923A2 (fr)
EA (1) EA202190153A1 (fr)
EC (1) ECSP21006416A (fr)
IL (1) IL279735A (fr)
MA (1) MA53010A (fr)
MX (1) MX2021000127A (fr)
PE (1) PE20211805A1 (fr)
PH (1) PH12020552274A1 (fr)
SG (1) SG11202013163TA (fr)
TW (1) TWI832871B (fr)
WO (1) WO2020006408A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
FI3436461T3 (fi) 2016-03-28 2024-01-16 Incyte Corp Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
GEP20227429B (en) * 2017-09-27 2022-10-25 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
EP4114401A1 (fr) 2020-03-06 2023-01-11 Incyte Corporation Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0395163A (ja) 1989-09-08 1991-04-19 Daicel Chem Ind Ltd ２．２．４．４．６―ペンタメチル―２．３．４．５―テトラヒドロピリミジンの製造法
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0859841B1 (fr) 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
CA2385769A1 (fr) 1999-09-17 2001-03-22 Gavin C. Hirst Inhibiteurs de kinase utilises comme agents therapeutiques
AU1560802A (en) 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
IL157898A0 (en) 2001-04-06 2004-03-28 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004065416A2 (fr) 2003-01-16 2004-08-05 Genentech, Inc. Banques de phages anticorps synthetiques
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
ATE399538T1 (de) 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
CA2536408A1 (fr) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
US20050203063A1 (en) 2003-09-12 2005-09-15 Raymond Deshaies Proteasome pathway inhibitors and related methods
MY143225A (en) 2004-04-02 2011-03-31 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
RS51843B (en) 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. CONDENSED BICYCLIC m TOR INHIBITORS
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
JP5400388B2 (ja) 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用
ATE542823T1 (de) 2006-04-12 2012-02-15 Vertex Pharma 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
ATE528002T1 (de) 2006-05-19 2011-10-15 Bayer Pharma AG Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
WO2008045978A1 (fr) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Dérivés de pyrimidinediamine substitués par du pinane, utiles en tant qu'inhibiteurs de axl
AU2007334379B2 (en) 2006-12-14 2013-04-18 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
PL2078010T3 (pl) 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl
WO2008083354A1 (fr) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Triazoles substitués par n3-hétéroaryle et triazoles substitués par n5-hétéroaryle utiles comme inhibiteurs de axl
CA2710043C (fr) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Triazoles a substitution aryle bicycliques et heteroaryle bicycliques utiles en tant qu'inhibiteurs axl
WO2008098139A2 (fr) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Inhibiteurs des récepteurs axl à activité tyrosine kinase et procédés de fabrication et d'utilisation de ceux-ci
KR20100014629A (ko) 2007-03-29 2010-02-10 파나세아 바이오테크 리미티드 타크로리무스의 변형제형
MX2009013565A (es) 2007-06-12 2010-06-02 Concert Pharmaceuticals Inc Derivados de azapeptidos.
CA2695753A1 (fr) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Composes utilises comme inhibiteurs de proteines kinases
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
SI2205592T1 (sl) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji
JP5537439B2 (ja) 2007-12-19 2014-07-02 アムジエン・インコーポレーテツド 細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
CN102131783A (zh) 2008-04-16 2011-07-20 马克斯普朗克科学发展组织 作为axl激酶抑制剂的喹啉衍生物
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
WO2010005879A1 (fr) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Triazoles substitués par hétéroaryle bicycliques pontés utiles comme inhibiteurs de axl
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
WO2010014755A1 (fr) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Procédés et composés permettant d’optimiser le traitement contre le cancer
EP2158913A1 (fr) 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
US20100075973A1 (en) 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2010071885A1 (fr) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines en tant qu'inhibiteurs d'alk et de jak2
EP2393814A1 (fr) 2009-02-09 2011-12-14 SuperGen, Inc. Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
RU2012116526A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
EP2311809A1 (fr) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
KR20220015492A (ko) 2010-03-10 2022-02-08 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
WO2011123493A1 (fr) 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Pyrrolotriazines substituées à titre d'inhibiteurs de protéines kinases
CA2761074A1 (fr) 2010-05-05 2011-11-10 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidines 4-substituees pouvant etre employees en tant qu'inhibiteurs de pkc-theta
EP2423208A1 (fr) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl
BR112013008526A2 (pt) 2010-10-08 2016-07-12 Elan Pharm Inc inibidores de quinase do tipo polo
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak
EP2655374B1 (fr) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
AU2012223639B2 (en) 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
EP2937349B1 (fr) 2011-03-23 2016-12-28 Amgen Inc. Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et flt3
EP2693881B1 (fr) 2011-04-01 2019-09-04 University of Utah Research Foundation Analogues de n-phénylpyrimidine-2-amine substitués en tant qu'inhibiteurs de l'axl kinase
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
EP2721028B1 (fr) 2011-06-20 2015-11-04 Incyte Corporation Dérivés d'azétidinyl-phényl-, de pyridyl- ou de pyrazinyl-carboxamide en tant qu'inhibiteurs des jak
PE20140570A1 (es) 2011-07-01 2014-04-28 Bayer Ip Gmbh Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR102371532B1 (ko) 2011-09-02 2022-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
DK2758052T3 (en) 2011-09-18 2018-05-28 Euro Celtique Sa Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
ES2650630T3 (es) 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Compuestos de pirrolopirimidina para el tratamiento del cáncer
PL2780338T3 (pl) 2011-11-14 2017-04-28 Ignyta, Inc. Pochodne uracylu jako inhibitory kinaz AXL i c-MET
AP2014007662A0 (en) 2011-11-29 2014-05-31 Perosphere Inc Anticoagulant reversal agents
WO2013085802A1 (fr) 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines en tant qu'inhibiteurs de kinase janus
MY165215A (en) 2012-01-31 2018-03-09 Daiichi Sankyo Co Ltd Pyridone derivatives
ES2581065T3 (es) 2012-02-23 2016-08-31 Bayer Intellectual Property Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
WO2013162061A1 (fr) 2012-04-26 2013-10-31 第一三共株式会社 Composé de pyrimidine bicyclique
WO2013173720A1 (fr) 2012-05-18 2013-11-21 Incyte Corporation Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
WO2014062774A1 (fr) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Composés pyrazolopyrimidines pour le traitement du cancer
NZ707495A (en) 2012-11-01 2019-01-25 Incyte Holdings Corp Tricyclic fused thiophene derivatives as jak inhibitors
US9925193B2 (en) 2012-11-20 2018-03-27 Proqinase Gmbh Thioether derivatives as protein kinase inhibitors
WO2014109858A1 (fr) 2013-01-14 2014-07-17 Amgen Inc. Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
TW201522337A (zh) 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並－嘧啶化合物類
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
ES2685661T3 (es) 2013-11-08 2018-10-10 Ono Pharmaceutical Co., Ltd. Derivado de pirrolopirimidina
AU2015225745B2 (en) 2014-02-03 2017-04-20 Cadila Healthcare Limited Heterocyclic compounds
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
EP3233829B1 (fr) 2014-12-18 2019-08-14 Pfizer Inc Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
WO2016183071A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Composés hétéro-tricycliques substitués et utilisation de ces composés pour le traitement du cancer
SI3456346T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh
WO2017027717A1 (fr) 2015-08-12 2017-02-16 Incyte Corporation Composés de pyrimidine fusionnés bicycliques utilisés en tant qu'inhibiteurs de tam
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
WO2017062797A1 (fr) 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill Méthodes de traitement de tumeurs
JP6488402B2 (ja) 2015-10-13 2019-03-20 日本農薬株式会社 オキシム基を有する縮合複素環化合物又はその塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
JP6921818B2 (ja) 2015-11-14 2021-08-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
EP3373934B1 (fr) 2015-11-14 2020-05-20 Sunshine Lake Pharma Co., Ltd. Forme cristalline d'un composé de quinoléine substitué et compositions pharmaceutiques en contenant
FI3436461T3 (fi) 2016-03-28 2024-01-16 Incyte Corp Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
WO2017184934A1 (fr) 2016-04-22 2017-10-26 Incyte Corporation Formulations d'un inhibiteur de lsd1
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
IL308256A (en) 2016-07-15 2024-01-01 Ionis Pharmaceuticals Inc Compounds and Methods for Modulating SMN2
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
GEP20227429B (en) 2017-09-27 2022-10-25 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
EP4114401A1 (fr) 2020-03-06 2023-01-11 Incyte Corporation Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1

Also Published As

Publication number Publication date
CN113164398A (zh) 2021-07-23
BR112020026804A2 (pt) 2021-03-30
EP3813800A1 (fr) 2021-05-05
CA3105214A1 (fr) 2020-01-02
EA202190153A1 (ru) 2021-04-09
US20200000812A1 (en) 2020-01-02
SG11202013163TA (en) 2021-01-28
JP2021529765A (ja) 2021-11-04
JP7520732B2 (ja) 2024-07-23
WO2020006408A1 (fr) 2020-01-02
CL2020003397A1 (es) 2021-05-14
ECSP21006416A (es) 2021-04-29
IL279735A (en) 2021-03-01
KR20210049088A (ko) 2021-05-04
AU2019293618A1 (en) 2021-02-18
CN113164398B (zh) 2023-11-03
TW202010501A (zh) 2020-03-16
PE20211805A1 (es) 2021-09-14
CN117771250A (zh) 2024-03-29
TWI832871B (zh) 2024-02-21
US11918585B2 (en) 2024-03-05
AR117600A1 (es) 2021-08-18
CO2021000923A2 (es) 2021-04-30
PH12020552274A1 (en) 2021-06-28
MX2021000127A (es) 2021-03-29
US11241438B2 (en) 2022-02-08
US20220273663A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
MA53010A (fr) Formulations d'un inhibiteur de axl/mer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA51616A (fr) Inhibiteurs d'adn-pk
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49421A (fr) Formulations d'arn
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK4015003T3 (da) Forbedret antistof-oligonukleotid-konjugat
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
MA52413A (fr) Inhibiteurs de cd73
MA41252A (fr) Formes solides d'un inhibiteur d'ask 1
MA52546A (fr) Compositions ciblées
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA50456A (fr) Formulations d'un inhibiteur de kinase trk macrocyclique
MA51066A (fr) Inhibiteurs d'intégrine
MA55909A (fr) Inhibiteurs de cdk
SG11202008925VA (en) Inhibitors of micro-rna 22
MA49006A (fr) Inhibiteurs d'ip6k
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA52809A (fr) Inhibiteurs de sarm1
MA52813A (fr) Inhibiteurs de sarm1
GB201906551D0 (en) Training behavior of an agent
MA53129A (fr) Inhibiteurs de l'histone désacétylase
MA51611A (fr) Inhibiteurs de pi4kiiibêta
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta